Health Care & Life Sciences » Pharmaceuticals | InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB | Cash Flow

Fiscal year is January-December. All values SEK Thousands.
2014
2015
2016
2017
Net Income before Extraordinaries
10,395.00
29,881.00
41,275.00
72,759.00
Depreciation, Depletion & Amortization
111.00
95.00
67.00
11.00
Other Funds
4,475.00
-
-
27.00
Funds from Operations
14,759.00
29,786.00
41,208.00
72,721.00
Changes in Working Capital
6,544.00
7,176.00
9,338.00
4,536.00
Net Operating Cash Flow
8,215.00
36,962.00
31,870.00
68,185.00
Capital Expenditures
-
-
53.00
-
Net Investing Cash Flow
-
-
53.00
-
Net Financing Cash Flow
30,162.00
30.00
218,195.00
8.00
Net Change in Cash
21,947.00
36,932.00
186,272.00
68,177.00
Free Cash Flow
8,215.00
36,962.00
31,923.00
68,185.00
Change in Capital Stock
30,162.00
30.00
218,195.00
8.00

About InDex Pharmaceuticals Holding AB

View Profile
Address
Tomtebodavägen 23 A
Stockholm AB 171 77
Sweden
Employees -
Website http://www.indexpharma.com
Updated 09/14/2018
InDex Pharmaceuticals Holding AB discovers and develops drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and commercialization of scientific discoveries in the biomedical field. The firm also develops a platform of patent-protected substances, so-called deoxyribonucleic acid-based ImmunModulatory Sequences, with the potential to be used for the treatment of various immunological diseases.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.